diphenhydramine has been researched along with Breast Neoplasms in 20 studies
Diphenhydramine: A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.
diphenhydramine : An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug.
antitussive : An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with breast cancer who receive weekly paclitaxel therapy may experience deleterious effects associated with prophylactic dexamethasone use for 12 consecutive weeks." | 9.30 | The feasibility of dexamethasone omission in weekly paclitaxel treatment for breast cancer patients. ( Castro, SN; de Castro Baccarin, AL; de Iracema Gomes Cubero, D; Del Giglio, A; Irene, MN; Luz, AS; Móz, LES; Sordi, R, 2019) |
| "The present study investigated the efficacy and safety of weekly administration of paclitaxel (PTX) for 37 patients with advanced or recurrent breast cancer." | 9.12 | [A phase II study of weekly paclitaxel for advanced or recurrent breast cancer]. ( Imai, S; Jitsuko, A; Nishikawa, H; Otoshi, M; Takahara, S; Tsubono, M; Wada, Y, 2007) |
| "To evaluate the feasibility and efficacy of a biweekly schedule of paclitaxel in advanced or recurrent breast cancer, 18 patients were enrolled in this pilot study." | 7.71 | [Efficacy of biweekly paclitaxel therapy in advanced or recurrent breast cancer]. ( Bando, H; Hayashi, K; Kuroi, K; Saji, S; Tanaka, C; Toi, M, 2002) |
| "It is established that histamine in the concentration of 10(-4)-10(-5) M possesses an inhibitory effect in the lymphocyte adherence inhibition test in patients with breast cancer." | 7.67 | [Histamine-receptor sensitivity of lymphocytes in patients with early and advanced stage breast cancer]. ( Kharkevich, DD; Polevaia, EB, 1988) |
| "Paclitaxel was administered by 1 h intravenous infusion at a dose of 80 mg/m2 every week." | 6.71 | Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01). ( Inoue, K; Kai, T; Koh, J; Mihara, H; Mochizuki, H; Okubo, K; Saito, T; Sato, K; Tabei, T, 2003) |
| "A chart review of the breast cancer SLN database was performed; it included 2392 sequential patients who underwent SLN biopsy involving isosulfan blue dye at Memorial Sloan-Kettering Cancer Center from September 12, 1996, to August 17, 2000." | 5.31 | Isosulfan blue dye reactions during sentinel lymph node mapping for breast cancer. ( Borgen, PI; Cody, HS; Fey, J; Gemignani, M; Heerdt, AS; Montgomery, LL; Petrek, J; Port, E; Thorne, AC; Van Zee, KJ, 2002) |
| "Patients with breast cancer who receive weekly paclitaxel therapy may experience deleterious effects associated with prophylactic dexamethasone use for 12 consecutive weeks." | 5.30 | The feasibility of dexamethasone omission in weekly paclitaxel treatment for breast cancer patients. ( Castro, SN; de Castro Baccarin, AL; de Iracema Gomes Cubero, D; Del Giglio, A; Irene, MN; Luz, AS; Móz, LES; Sordi, R, 2019) |
| "The present study investigated the efficacy and safety of weekly administration of paclitaxel (PTX) for 37 patients with advanced or recurrent breast cancer." | 5.12 | [A phase II study of weekly paclitaxel for advanced or recurrent breast cancer]. ( Imai, S; Jitsuko, A; Nishikawa, H; Otoshi, M; Takahara, S; Tsubono, M; Wada, Y, 2007) |
| "Paclitaxel-based chemotherapy continues to be an integral component of breast cancer treatment." | 3.81 | Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. ( Berger, MJ; Layman, R; Lustberg, MB; Macrae, E; Mrozek, E; Phillips, G; Ramaswamy, B; Shapiro, CL; Shaver, K; Vargo, C; Vincent, M; Wesolowski, R, 2015) |
| "To evaluate the feasibility and efficacy of a biweekly schedule of paclitaxel in advanced or recurrent breast cancer, 18 patients were enrolled in this pilot study." | 3.71 | [Efficacy of biweekly paclitaxel therapy in advanced or recurrent breast cancer]. ( Bando, H; Hayashi, K; Kuroi, K; Saji, S; Tanaka, C; Toi, M, 2002) |
| "It is established that histamine in the concentration of 10(-4)-10(-5) M possesses an inhibitory effect in the lymphocyte adherence inhibition test in patients with breast cancer." | 3.67 | [Histamine-receptor sensitivity of lymphocytes in patients with early and advanced stage breast cancer]. ( Kharkevich, DD; Polevaia, EB, 1988) |
| "Paclitaxel was administered by 1 h intravenous infusion at a dose of 80 mg/m2 every week." | 2.71 | Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01). ( Inoue, K; Kai, T; Koh, J; Mihara, H; Mochizuki, H; Okubo, K; Saito, T; Sato, K; Tabei, T, 2003) |
| "Paclitaxel 135 mg/m2 was infused as a single dose over 1 hour or was divided into three doses infused over 1 hour on 3 consecutive days." | 2.68 | One-hour paclitaxel infusion schedules: a phase I/II comparative trial. ( Greco, FA; Hainsworth, JD, 1995) |
| "Docetaxel is active for metastatic breast cancer." | 2.68 | Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. ( Balmaceda, C; Baselga, J; Bruno, R; Crown, JP; Currie, V; Freilich, R; Gilewski, TA; Gollub, M; Hakes, TB; Hudis, CA; Lebwohl, DE; Norton, L; Raptis, G; Robles, M; Seidman, AD, 1996) |
| "Cimetidine-treated RBCs were optimally prepared at room temperature and needed to be tested on the day of preparation." | 1.36 | Immune hemolytic anemia due to cimetidine: the first example of a cimetidine antibody. ( Arndt, PA; Asuncion, DJ; Brasfield, FM; Garratty, G; Vemuri, SL, 2010) |
| "In 115/122 breast cancer patients not hypersensitive to initial PTX treatment, 20 mg dexamethasone (DXM) doses were tapered by 2." | 1.33 | Tapering and discontinuation of glucocorticoid prophylaxis during prolonged weekly to biweekly paclitaxel administration. ( Adamson, B; Braverman, AS; McManus, M; Pierre, S; Rao, S; Salvatti, ME, 2005) |
| "A chart review of the breast cancer SLN database was performed; it included 2392 sequential patients who underwent SLN biopsy involving isosulfan blue dye at Memorial Sloan-Kettering Cancer Center from September 12, 1996, to August 17, 2000." | 1.31 | Isosulfan blue dye reactions during sentinel lymph node mapping for breast cancer. ( Borgen, PI; Cody, HS; Fey, J; Gemignani, M; Heerdt, AS; Montgomery, LL; Petrek, J; Port, E; Thorne, AC; Van Zee, KJ, 2002) |
| " The BAD pump was safe and effective in minimizing nausea and vomiting associated with HDC, and thus, eliminated the need for hospitalization for management of chemotherapy-induced nausea and vomiting." | 1.30 | Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy. ( Belt, R; Coon, J; Cord, M; Dix, S; Geller, R; Howard, S, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (15.00) | 18.7374 |
| 1990's | 5 (25.00) | 18.2507 |
| 2000's | 6 (30.00) | 29.6817 |
| 2010's | 5 (25.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hamed, MM | 1 |
| Darwish, SS | 1 |
| Herrmann, J | 1 |
| Abadi, AH | 1 |
| Engel, M | 1 |
| Qutob, HMH | 1 |
| Saad, RA | 1 |
| Bali, H | 1 |
| Osailan, A | 1 |
| Jaber, J | 1 |
| Alzahrani, E | 1 |
| Alyami, J | 1 |
| Elsayed, H | 1 |
| Alserihi, R | 1 |
| Shaikhomar, OA | 1 |
| Divya, KM | 1 |
| Savitha, DP | 1 |
| Krishna, GA | 1 |
| Dhanya, TM | 1 |
| Mohanan, PV | 1 |
| Shah, SF | 1 |
| Jafry, AT | 1 |
| Hussain, G | 1 |
| Kazim, AH | 1 |
| Ali, M | 1 |
| Rivani, E | 1 |
| Endraswari, PD | 1 |
| Widodo, ADW | 1 |
| Khalil, MR | 1 |
| Guldberg, R | 1 |
| Nørgård, BM | 1 |
| Uldbjerg, N | 1 |
| Wehberg, S | 1 |
| Fowobaje, KR | 1 |
| Mashood, LO | 1 |
| Ekholuenetale, M | 1 |
| Ibidoja, OJ | 1 |
| Romagnoli, A | 1 |
| D'Agostino, M | 1 |
| Pavoni, E | 1 |
| Ardiccioni, C | 1 |
| Motta, S | 1 |
| Crippa, P | 1 |
| Biagetti, G | 1 |
| Notarstefano, V | 1 |
| Rexha, J | 1 |
| Perta, N | 1 |
| Barocci, S | 1 |
| Costabile, BK | 1 |
| Colasurdo, G | 1 |
| Caucci, S | 1 |
| Mencarelli, D | 1 |
| Turchetti, C | 1 |
| Farina, M | 1 |
| Pierantoni, L | 1 |
| La Teana, A | 1 |
| Al Hadi, R | 1 |
| Cicconardi, F | 1 |
| Chinappi, M | 1 |
| Trucchi, E | 1 |
| Mancia, F | 1 |
| Menzo, S | 1 |
| Morozzo Della Rocca, B | 1 |
| D'Annessa, I | 1 |
| Di Marino, D | 1 |
| Choya, A | 1 |
| de Rivas, B | 1 |
| Gutiérrez-Ortiz, JI | 1 |
| López-Fonseca, R | 1 |
| Xu, S | 1 |
| Cheng, B | 1 |
| Huang, Z | 1 |
| Liu, T | 1 |
| Li, Y | 1 |
| Jiang, L | 1 |
| Guo, W | 1 |
| Xiong, J | 1 |
| Amirazodi, M | 1 |
| Daryanoosh, F | 1 |
| Mehrabi, A | 1 |
| Gaeini, A | 1 |
| Koushkie Jahromi, M | 1 |
| Salesi, M | 1 |
| Zarifkar, AH | 1 |
| Studeny, P | 1 |
| Netukova, M | 1 |
| Nemcokova, M | 1 |
| Klimesova, YM | 1 |
| Krizova, D | 1 |
| Kang, H | 1 |
| Tao, Y | 1 |
| Zhang, Q | 1 |
| Sha, D | 1 |
| Chen, Y | 1 |
| Yao, J | 1 |
| Gao, Y | 1 |
| Liu, J | 1 |
| Ji, L | 1 |
| Shi, P | 1 |
| Shi, C | 1 |
| Wu, YL | 1 |
| Wright, AI | 1 |
| M El-Metwaly, N | 1 |
| A Katouah, H | 1 |
| El-Desouky, MG | 1 |
| El-Bindary, AA | 1 |
| El-Bindary, MA | 1 |
| Kostakis, ID | 1 |
| Raptis, DA | 1 |
| Davidson, BR | 1 |
| Iype, S | 1 |
| Nasralla, D | 1 |
| Imber, C | 1 |
| Sharma, D | 1 |
| Pissanou, T | 1 |
| Pollok, JM | 1 |
| Hughes, AM | 1 |
| Sanderson, E | 1 |
| Morris, T | 1 |
| Ayorech, Z | 1 |
| Tesli, M | 1 |
| Ask, H | 1 |
| Reichborn-Kjennerud, T | 1 |
| Andreassen, OA | 1 |
| Magnus, P | 1 |
| Helgeland, Ø | 1 |
| Johansson, S | 1 |
| Njølstad, P | 1 |
| Davey Smith, G | 1 |
| Havdahl, A | 1 |
| Howe, LD | 1 |
| Davies, NM | 1 |
| Amrillah, T | 1 |
| Prasetio, A | 1 |
| Supandi, AR | 1 |
| Sidiq, DH | 1 |
| Putra, FS | 1 |
| Nugroho, MA | 1 |
| Salsabilla, Z | 1 |
| Azmi, R | 1 |
| Grammatikopoulos, P | 1 |
| Bouloumis, T | 1 |
| Steinhauer, S | 1 |
| Mironov, VS | 2 |
| Bazhenova, TA | 2 |
| Manakin, YV | 2 |
| Yagubskii, EB | 2 |
| Yakushev, IA | 1 |
| Gilmutdinov, IF | 1 |
| Simonov, SV | 1 |
| Lan, K | 1 |
| Yang, H | 1 |
| Zheng, J | 1 |
| Hu, H | 1 |
| Zhu, T | 1 |
| Zou, X | 1 |
| Hu, B | 1 |
| Liu, H | 1 |
| Olokede, O | 1 |
| Wu, H | 1 |
| Holtzapple, M | 1 |
| Gungor, O | 1 |
| Kose, M | 1 |
| Ghaemi, R | 1 |
| Acker, M | 1 |
| Stosic, A | 1 |
| Jacobs, R | 1 |
| Selvaganapathy, PR | 1 |
| Ludwig, N | 1 |
| Yerneni, SS | 1 |
| Azambuja, JH | 1 |
| Pietrowska, M | 1 |
| Widłak, P | 1 |
| Hinck, CS | 1 |
| Głuszko, A | 1 |
| Szczepański, MJ | 1 |
| Kärmer, T | 1 |
| Kallinger, I | 1 |
| Schulz, D | 1 |
| Bauer, RJ | 1 |
| Spanier, G | 1 |
| Spoerl, S | 1 |
| Meier, JK | 1 |
| Ettl, T | 1 |
| Razzo, BM | 1 |
| Reichert, TE | 1 |
| Hinck, AP | 1 |
| Whiteside, TL | 1 |
| Wei, ZL | 1 |
| Juan, W | 1 |
| Tong, D | 1 |
| Juan, LX | 1 |
| Sa, LY | 1 |
| Jie, HFM | 1 |
| Xiao, G | 1 |
| Xiang, LG | 1 |
| Jie, HM | 1 |
| Xu, C | 1 |
| Yu, DN | 1 |
| Yao, ZX | 1 |
| Bigdeli, F | 1 |
| Gao, XM | 1 |
| Cheng, X | 1 |
| Li, JZ | 1 |
| Zhang, JW | 1 |
| Wang, W | 2 |
| Guan, ZJ | 1 |
| Bu, Y | 1 |
| Liu, KG | 1 |
| Morsali, A | 1 |
| Das, R | 1 |
| Paul, R | 1 |
| Parui, A | 1 |
| Shrotri, A | 1 |
| Atzori, C | 1 |
| Lomachenko, KA | 1 |
| Singh, AK | 1 |
| Mondal, J | 1 |
| Peter, SC | 1 |
| Florimbio, AR | 1 |
| Coughlin, LN | 1 |
| Bauermeister, JA | 1 |
| Young, SD | 1 |
| Zimmerman, MA | 1 |
| Walton, MA | 1 |
| Bonar, EE | 1 |
| Demir, D | 1 |
| Balci, AB | 1 |
| Kahraman, N | 1 |
| Sunbul, SA | 1 |
| Gucu, A | 1 |
| Seker, IB | 1 |
| Badem, S | 1 |
| Yuksel, A | 1 |
| Ozyazicioglu, AF | 1 |
| Goncu, MT | 1 |
| Zhang, H | 1 |
| Zhou, H | 1 |
| Deng, Z | 1 |
| Luo, L | 1 |
| Ong, SP | 1 |
| Wang, C | 1 |
| Xin, H | 1 |
| Whittingham, MS | 1 |
| Zhou, G | 1 |
| Maemura, R | 1 |
| Wakamatsu, M | 1 |
| Matsumoto, K | 1 |
| Sakaguchi, H | 1 |
| Yoshida, N | 1 |
| Hama, A | 1 |
| Yoshida, T | 1 |
| Miwata, S | 1 |
| Kitazawa, H | 1 |
| Narita, K | 1 |
| Kataoka, S | 1 |
| Ichikawa, D | 1 |
| Hamada, M | 1 |
| Taniguchi, R | 1 |
| Suzuki, K | 1 |
| Kawashima, N | 1 |
| Nishikawa, E | 1 |
| Narita, A | 1 |
| Okuno, Y | 1 |
| Nishio, N | 1 |
| Kato, K | 1 |
| Kojima, S | 1 |
| Morita, K | 1 |
| Muramatsu, H | 1 |
| Takahashi, Y | 1 |
| Yirgu, A | 1 |
| Mekonnen, Y | 1 |
| Eyado, A | 1 |
| Staropoli, A | 1 |
| Vinale, F | 1 |
| Zac, J | 1 |
| Zac, S | 1 |
| Pérez-Padilla, R | 1 |
| Remigio-Luna, A | 1 |
| Guzmán-Boulloud, N | 1 |
| Gochicoa-Rangel, L | 1 |
| Guzmán-Valderrábano, C | 1 |
| Thirión-Romero, I | 1 |
| Statsenko, ME | 1 |
| Turkina, SV | 1 |
| Barantsevich, ER | 1 |
| Karakulova, YV | 1 |
| Baranova, NS | 1 |
| Morzhukhina, MV | 1 |
| Wang, Q | 1 |
| Gu, Y | 1 |
| Chen, C | 1 |
| Qiao, L | 1 |
| Pan, F | 1 |
| Song, C | 1 |
| Canetto, SS | 1 |
| Entilli, L | 1 |
| Cerbo, I | 1 |
| Cipolletta, S | 1 |
| Wu, Y | 2 |
| Zhu, P | 1 |
| Jiang, Y | 1 |
| Zhang, X | 1 |
| Wang, Z | 1 |
| Xie, B | 1 |
| Song, T | 1 |
| Zhang, F | 1 |
| Luo, A | 1 |
| Li, S | 1 |
| Xiong, X | 1 |
| Han, J | 1 |
| Peng, X | 1 |
| Li, M | 1 |
| Huang, L | 1 |
| Chen, Q | 1 |
| Fang, W | 1 |
| Hou, Y | 1 |
| Zhu, Y | 1 |
| Ye, J | 1 |
| Liu, L | 1 |
| Islam, MR | 1 |
| Sanderson, P | 1 |
| Johansen, MP | 1 |
| Payne, TE | 1 |
| Naidu, R | 1 |
| Cao, J | 1 |
| Yang, J | 1 |
| Niu, X | 1 |
| Liu, X | 1 |
| Zhai, Y | 1 |
| Qiang, C | 1 |
| Niu, Y | 1 |
| Li, Z | 1 |
| Dong, N | 1 |
| Wen, B | 1 |
| Ouyang, Z | 1 |
| Zhang, Y | 1 |
| Li, J | 2 |
| Zhao, M | 1 |
| Zhao, J | 1 |
| Morici, P | 1 |
| Rizzato, C | 1 |
| Ghelardi, E | 1 |
| Rossolini, GM | 1 |
| Lupetti, A | 1 |
| Gözüküçük, R | 1 |
| Cakiroglu, B | 1 |
| He, X | 1 |
| Li, R | 1 |
| Zhao, D | 1 |
| Zhang, L | 1 |
| Ji, X | 1 |
| Fan, X | 1 |
| Chen, J | 1 |
| Wang, Y | 1 |
| Luo, Y | 1 |
| Zheng, D | 1 |
| Xie, L | 1 |
| Sun, S | 1 |
| Cai, Z | 1 |
| Liu, Q | 1 |
| Ma, K | 1 |
| Sun, X | 1 |
| Drinkwater, JJ | 1 |
| Davis, TME | 1 |
| Turner, AW | 1 |
| Davis, WA | 1 |
| Suzuki, Y | 1 |
| Mizuta, Y | 1 |
| Mikagi, A | 1 |
| Misawa-Suzuki, T | 1 |
| Tsuchido, Y | 1 |
| Sugaya, T | 1 |
| Hashimoto, T | 1 |
| Ema, K | 1 |
| Hayashita, T | 1 |
| de Castro Baccarin, AL | 1 |
| Irene, MN | 1 |
| de Iracema Gomes Cubero, D | 1 |
| Luz, AS | 1 |
| Castro, SN | 1 |
| Sordi, R | 1 |
| Móz, LES | 1 |
| Del Giglio, A | 1 |
| Berger, MJ | 1 |
| Vargo, C | 1 |
| Vincent, M | 1 |
| Shaver, K | 1 |
| Phillips, G | 1 |
| Layman, R | 1 |
| Macrae, E | 1 |
| Mrozek, E | 1 |
| Ramaswamy, B | 1 |
| Wesolowski, R | 1 |
| Shapiro, CL | 1 |
| Lustberg, MB | 1 |
| Arndt, PA | 1 |
| Garratty, G | 1 |
| Brasfield, FM | 1 |
| Vemuri, SL | 1 |
| Asuncion, DJ | 1 |
| Rabaglio, M | 1 |
| Ruepp, B | 1 |
| Montgomery, LL | 1 |
| Thorne, AC | 1 |
| Van Zee, KJ | 1 |
| Fey, J | 1 |
| Heerdt, AS | 1 |
| Gemignani, M | 1 |
| Port, E | 1 |
| Petrek, J | 1 |
| Cody, HS | 1 |
| Borgen, PI | 1 |
| BRENNIG, K | 1 |
| Sato, K | 1 |
| Inoue, K | 1 |
| Saito, T | 1 |
| Kai, T | 1 |
| Mihara, H | 1 |
| Okubo, K | 1 |
| Koh, J | 1 |
| Mochizuki, H | 1 |
| Tabei, T | 1 |
| Braverman, AS | 1 |
| Rao, S | 1 |
| Salvatti, ME | 1 |
| Adamson, B | 1 |
| McManus, M | 1 |
| Pierre, S | 1 |
| Wada, Y | 1 |
| Otoshi, M | 1 |
| Jitsuko, A | 1 |
| Nishikawa, H | 1 |
| Takahara, S | 1 |
| Tsubono, M | 1 |
| Imai, S | 1 |
| Greco, FA | 2 |
| Hainsworth, JD | 2 |
| Hudis, CA | 1 |
| Seidman, AD | 1 |
| Crown, JP | 1 |
| Balmaceda, C | 1 |
| Freilich, R | 1 |
| Gilewski, TA | 1 |
| Hakes, TB | 1 |
| Currie, V | 1 |
| Lebwohl, DE | 1 |
| Baselga, J | 1 |
| Raptis, G | 1 |
| Gollub, M | 1 |
| Robles, M | 1 |
| Bruno, R | 1 |
| Norton, L | 1 |
| Chan, AT | 1 |
| Yeo, W | 1 |
| Leung, WT | 1 |
| Johnson, PJ | 1 |
| Dix, S | 1 |
| Cord, M | 1 |
| Howard, S | 1 |
| Coon, J | 1 |
| Belt, R | 1 |
| Geller, R | 1 |
| Kuroi, K | 1 |
| Tanaka, C | 1 |
| Bando, H | 1 |
| Saji, S | 1 |
| Hayashi, K | 1 |
| Toi, M | 1 |
| Uno, Y | 1 |
| Hirano, M | 1 |
| Murakami, N | 1 |
| Kikuchi, T | 1 |
| Nozawa, H | 1 |
| Okuda, T | 1 |
| Oya, J | 1 |
| Kikkawa, H | 1 |
| White, MJ | 1 |
| Miller, FN | 1 |
| Heuser, LS | 1 |
| Pietsch, CG | 1 |
| Kharkevich, DD | 1 |
| Polevaia, EB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer[NCT04669132] | Phase 2 | 50 participants (Actual) | Interventional | 2020-12-17 | Completed | ||
| Feasibility of a Randomized Controlled Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel[NCT04237090] | Phase 3 | 27 participants (Actual) | Interventional | 2020-02-14 | Completed | ||
| A Phase III Trial Evaluating The Role Of Exemestane Plus GnRH Analogue As Adjuvant Therapy For Premenopausal Women With Endocrine Responsive Breast Cancer[NCT00066703] | Phase 3 | 2,672 participants (Actual) | Interventional | 2003-11-03 | Active, not recruiting | ||
| Adjuvant Dose-dense Sequential Chemotherapy With Epirubicin, CMF, and Weekly Docetaxel or Weekly Paclitaxel in Patients With Resected High-risk Breast Cancer: A Hellenic Cooperative Oncology Group (HeCOG) Study[NCT04829890] | 89 participants (Actual) | Observational | 2004-02-29 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Estimated percentage of patients alive and disease-free at 5 years from randomization, where breast cancer-free interval is defined as the time from randomization to the invasive breast cancer recurrence at local, regional, or distant site, or invasive contralateral breast cancer; or censored at date of last follow up. (NCT00066703)
Timeframe: 5-year estimate reported at a median follow-up of 72 months
| Intervention | percentage of participants (Number) |
|---|---|
| T+OFS | 88.8 |
| E+OFS | 92.8 |
Estimated percentage of patients alive and disease-free at 5 years from randomization, where disease-free survival is defined as the time from randomization to the first appearance of one of the following: invasive breast cancer recurrence at local, regional, or distant site, invasive contralateral breast cancer, second (non-breast) invasive cancer, or death without cancer event; or censored at date of last follow up. (NCT00066703)
Timeframe: 5-year estimate reported at a median follow-up of 72 months
| Intervention | percentage of participants (Number) |
|---|---|
| T+OFS | 87.3 |
| E+OFS | 91.1 |
Estimated percentage of patients alive and disease-free at 5 years from randomization, where distant recurrence-free interval is defined as the time from randomization to breast cancer recurrence at a distant site; or censored at date of last follow-up (NCT00066703)
Timeframe: 5-year estimates reported at a median follow-up of 72 months
| Intervention | percentage of participants (Number) |
|---|---|
| T+OFS | 92.0 |
| E+OFS | 93.8 |
Estimated percentage of patients alive at 8 years from randomization, where overall survival is defined as the time from randomization to death from any cause; or censored at date last known alive. (NCT00066703)
Timeframe: 8-year estimates, reported at a median follow-up of 9 years
| Intervention | percentage of participants (Number) |
|---|---|
| T+OFS | 93.3 |
| E+OFS | 93.4 |
1 review available for diphenhydramine and Breast Neoplasms
| Article | Year |
|---|---|
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter | 2022 |
8 trials available for diphenhydramine and Breast Neoplasms
| Article | Year |
|---|---|
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter | 2022 |
The feasibility of dexamethasone omission in weekly paclitaxel treatment for breast cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; D | 2019 |
Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01).
Topics: Adult; Aged; Alopecia; Antiemetics; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethaso | 2003 |
[A phase II study of weekly paclitaxel for advanced or recurrent breast cancer].
Topics: Adult; Aged; Alopecia; Antiemetics; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neopla | 2007 |
One-hour paclitaxel infusion schedules: a phase I/II comparative trial.
Topics: Blood Cell Count; Breast Neoplasms; Cimetidine; Dexamethasone; Diphenhydramine; Drug Administration | 1995 |
Paclitaxel administered by 1-hour infusion. Preliminary results of a phase I/II trial comparing two schedules.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cimetidine; Dexamethasone; Diphenhydr | 1994 |
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cimetidine; Dexamethasone; Diphenh | 1996 |
[Weekly administration of low-dose paclitaxel for advanced or metastatic breast cancer].
Topics: Aged; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethasone; Diphenhydramine; | 2002 |
12 other studies available for diphenhydramine and Breast Neoplasms
| Article | Year |
|---|---|
First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.
Topics: Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Cell Line, Tumor; ErbB Receptors; Female; | 2017 |
Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2015 |
Immune hemolytic anemia due to cimetidine: the first example of a cimetidine antibody.
Topics: Anemia, Hemolytic; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Breast Neoplas | 2010 |
Death due to liver failure during endocrine therapy for premenopausal breast cancer.
Topics: Adult; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chem | 2010 |
Isosulfan blue dye reactions during sentinel lymph node mapping for breast cancer.
Topics: Anaphylaxis; Anesthesia; Breast Neoplasms; Coloring Agents; Cross Reactions; Databases, Factual; Dip | 2002 |
[CLINICAL STUDIES WITH VOYAL IN RADIATION INJURIES].
Topics: Breast Neoplasms; Diphenhydramine; Female; Humans; Lung Neoplasms; Radiation Injuries; Theophylline; | 1963 |
Tapering and discontinuation of glucocorticoid prophylaxis during prolonged weekly to biweekly paclitaxel administration.
Topics: Adult; Aged; Aged, 80 and over; Anti-Allergic Agents; Anti-Inflammatory Agents; Antineoplastic Agent | 2005 |
Thromboembolic events with paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cerebral Infarction; Diphenhydramine; Female; H | 1996 |
Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy.
Topics: Adult; Ambulatory Care; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasm | 1999 |
[Efficacy of biweekly paclitaxel therapy in advanced or recurrent breast cancer].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethasone; Diphen | 2002 |
Human malignant ascites and histamine-induced protein leakage from the normal microcirculation.
Topics: Animals; Ascites; Bradykinin; Breast Neoplasms; Capillary Permeability; Complement C3; Complement C3 | 1988 |
[Histamine-receptor sensitivity of lymphocytes in patients with early and advanced stage breast cancer].
Topics: Breast Neoplasms; Cimetidine; Diphenhydramine; Female; Histamine; Humans; In Vitro Techniques; Leuko | 1988 |